Search

Your search keyword '"Viberti GC"' showing total 81 results

Search Constraints

Start Over You searched for: Author "Viberti GC" Remove constraint Author: "Viberti GC" Search Limiters Full Text Remove constraint Search Limiters: Full Text
81 results on '"Viberti GC"'

Search Results

1. Repeatability of three-day dietary records in the EURODIAB IDDM Complications Study

2. Fibrinogen and von Willebrand factor in IDDM: relationships to lipid vascular risk factors, blood pressure, glycaemic control and urinary albumin excretion rate: the EURODIAB IDDM Complications Study

3. Nutritional intake of 2868 IDDM patients from 30 centres in Europe

4. Cardiovascular disease and its risk factors in IDDM in Europe

6. BLOOD-PRESSURE, RETINOPATHY AND URINARY ALBUMIN EXCRETION IN IDDM - THE EURODIAB IDDM COMPLICATIONS STUDY

7. A PC-1 amino acid variant (K121Q) is associated with faster progression of renal disease in patients with type 1 diabetes and albuminuria

10. Neovasularization at the vascular pole region in diabetic glomerulopathy.

11. Selective and extremely long inhibition of prolactin release in man by 1-ethyl-3-(3′-dimethylaminopropyl)-3-(6′-allylergoline-8′-beta- carbonyl)-urea-diphosphate (FCE 21336).

12. A genome-wide association study of diabetic kidney disease in subjects with type 2 diabetes

14. High prevalence of risk factors for cardiovascular disease in parents of IDDM patients with albuminuria

15. Determinants of urinary albumin excretion within the normal range in patients with type 2 diabetes: the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study.

16. Evaluation of rosiglitazone administration on cardiovascular function in severe obesity.

17. Genetic association analyses of non-synonymous single nucleotide polymorphisms in diabetic nephropathy.

18. Comment on: Boden et al. (2007) Combined use of rosiglitazone and fenofibrate in patients with type 2 diabetes: prevention of fluid retention: Diabetes 56:248-255.

19. No change in glomerular heparan sulfate structure in early human and experimental diabetic nephropathy.

20. Obesity is a major determinant of the association of C-reactive protein levels and the metabolic syndrome in type 2 diabetes.

21. Metabolic syndrome in obese Caucasian children: prevalence using WHO-derived criteria and association with nontraditional cardiovascular risk factors.

22. -to: Ong KK, Petry CJ, Emmett PM et al.; ALSPAC study team (2004) Insulin sensitivity and secretion in normal children related to size at birth, postnatal growth, and plasma insulin-like growth factor-I levels. Diabetologia 47:1064-1070.

23. Lack of evidence for the 1484insG variant at the 3'-UTR of the protein tyrosine phosphatase 1B (PTP1B) gene as a genetic determinant of diabetic nephropathy development in type 1 diabetic patients.

24. P38 mitogen-activated protein kinase mediates hexosamine-induced TGFbeta1 mRNA expression in human mesangial cells.

25. Subclinical hypothyroidism in obese patients: relation to resting energy expenditure, serum leptin, body composition, and lipid profile.

26. Defective intracellular antioxidant enzyme production in type 1 diabetic patients with nephropathy.

28. Low-dose ramipril reduces microalbuminuria in type 1 diabetic patients without hypertension: results of a randomized controlled trial.

29. Role of insulin-like growth factor (IGF)-1 in the modulation of renal haemodynamics in Type I diabetic patients.

30. Proteinuria in diabetes.

31. Determinants of elevated urinary albumin in the 4,937 type 2 diabetic subjects recruited for the DIABHYCAR Study in Western Europe and North Africa.

32. Mechanical stretch-induced fibronectin and transforming growth factor-beta1 production in human mesangial cells is p38 mitogen-activated protein kinase-dependent.

33. A PC-1 amino acid variant (K121Q) is associated with faster progression of renal disease in patients with type 1 diabetes and albuminuria.

34. High prevalence of risk factors for cardiovascular disease in parents of IDDM patients with albuminuria.

35. Modelling and costing the consequences of using an ACE inhibitor to slow the progression of renal failure in type I diabetic patients.

36. Premature cell ageing and evolution of diabetic nephropathy.

37. Promoters of progression of diabetic nephropathy: the relative roles of blood glucose and blood pressure control.

38. Microalbuminuria as a marker of silent myocardial ischaemia in IDDM patients.

39. Elevated serum levels of macrophage-derived cytokines precede and accompany the onset of IDDM.

40. Glomerular epithelial foot processes and filtration slits in IDDM patients.

41. Blood pressure, retinopathy and urinary albumin excretion in IDDM: the EURODIAB IDDM Complications Study.

42. Monitoring kidney function in diabetic nephropathy.

43. LDL subclasses in IDDM patients: relation to diabetic nephropathy.

45. Familial, hemodynamic and metabolic factors in the predisposition to diabetic kidney disease.

46. Storage temperature and differing methods of sample preparation in the measurement of urinary albumin.

47. Glucose-induced changes in renal haemodynamics in proteinuric type 1 (insulin-dependent) diabetic patients: inhibition by acetylsalicilic acid infusion.

48. Is screening and intervention for microalbuminuria worthwhile in patients with insulin dependent diabetes?

50. Prognostic significance of microalbuminuria in insulin-dependent diabetes mellitus: a twenty-three year follow-up study.

Catalog

Books, media, physical & digital resources